Financial giants have made a conspicuous bearish move on Amgen. Our analysis of options history for Amgen AMGN revealed 11 unusual trades.
Delving into the details, we found 36% of traders were bullish, while 63% showed bearish tendencies. Out of all the trades we spotted, 9 were puts, with a value of $445,336, and 2 were calls, valued at $110,875.
What's The Price Target?
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $230.0 to $285.0 for Amgen over the recent three months.
Insights into Volume & Open Interest
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Amgen's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Amgen's whale activity within a strike price range from $230.0 to $285.0 in the last 30 days.
Amgen Option Volume And Open Interest Over Last 30 Days
Significant Options Trades Detected:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|
| AMGN | PUT | SWEEP | NEUTRAL | 07/19/24 | $255.00 | $81.0K | 130 | 111 |
| AMGN | PUT | TRADE | BULLISH | 04/05/24 | $280.00 | $76.4K | 113 | 98 |
| AMGN | PUT | TRADE | BEARISH | 01/17/25 | $270.00 | $65.7K | 1.9K | 0 |
| AMGN | CALL | SWEEP | BEARISH | 01/17/25 | $280.00 | $60.8K | 1.4K | 30 |
| AMGN | PUT | SWEEP | BEARISH | 01/17/25 | $230.00 | $54.0K | 397 | 60 |
About Amgen
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
After a thorough review of the options trading surrounding Amgen, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
Amgen's Current Market Status
- Currently trading with a volume of 2,365,437, the AMGN's price is down by -1.61%, now at $271.54.
- RSI readings suggest the stock is currently may be approaching oversold.
- Anticipated earnings release is in 42 days.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Amgen, Benzinga Pro gives you real-time options trades alerts.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
